Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Phase: N/A Priority: Normal
NCT ID: NCT04227106 Org: User:
Start: 01/10/20 End: 10/18/22 Due: 10/18/23

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Phase: N/A Priority: Normal
NCT ID: NCT04655911 Org: User:
Start: 10/28/20 End: 04/07/22 Due: 04/07/23

A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

Phase: N/A Priority: Normal
NCT ID: NCT00385502 Org: User:
Start: 09/30/06 End: 06/30/08 Due: 06/30/09

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Phase: N/A Priority: Normal
NCT ID: NCT05725018 Org: User:
Start: 04/02/23 End: 09/30/25 Due: 09/30/26

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Phase: N/A Priority: Normal
NCT ID: NCT00563433 Org: User:
Start: 08/31/94 End: 07/31/96 Due: 07/31/97

Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB

Phase: N/A Priority: Normal
NCT ID: NCT03315182 Org: User:
Start: 10/16/17 End: 04/07/22 Due: 04/07/23

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

Phase: N/A Priority: Normal
NCT ID: NCT05708677 Org: User:
Start: 02/09/21 End: 08/31/36 Due: 08/31/37

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Phase: N/A Priority: Normal
NCT ID: NCT01263379 Org: User:
Start: 10/05/10 End: 03/09/22 Due: 03/09/23

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Phase: N/A Priority: Normal
NCT ID: NCT00563394 Org: User:
Start: 08/31/94 End: 07/31/96 Due: 07/31/97